Neuroendocrine Tumor Therapy Response Assessment

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Peptide receptor radionuclide therapy (PRRT) is integral to managing neuroendocrine neoplasms (NENs).
• Gallium-68- and Lutetium-177-labeled somatostatin receptor analogues are now standard, replacing older tracers.
• Emerging targeted therapies require precise response evaluation.

Purpose of the Study:

• To provide an overview of biomarkers for assessing treatment response in NENs.
• To discuss the strengths and weaknesses of current response assessment biomarkers.
• To address the challenges in evaluating PRRT and targeted therapy efficacy in NENs.

Main Methods:

• Literature review of PRRT and targeted therapies for NENs.
• Analysis of biomarker utility in response assessment.
• Discussion of NEN characteristics influencing response patterns.

Main Results:

• PRRT with Ga-68 and Lu-177 analogues is a primary treatment modality.
• Accurate response assessment is crucial but challenging due to NEN heterogeneity.
• Various biomarkers exist, each with distinct advantages and limitations.

Conclusions:

• Effective management of NENs relies on accurate response assessment to PRRT and targeted therapies.
• Understanding biomarker characteristics is essential for clinical decision-making.
• Further research may refine response evaluation in NENs.